Drug Profile
Peginterferon alfa-2b biosimilar - Phage Pharmaceuticals
Latest Information Update: 12 Jan 2022
Price :
$50
*
At a glance
- Originator Phage Pharmaceuticals
- Class Antineoplastics; Antiretrovirals; Antivirals; Immunotherapies; Interferons; Polyethylene glycols; Skin disorder therapies
- Mechanism of Action Immunostimulants; Interferon alpha stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hepatitis
Most Recent Events
- 08 Jun 2015 No development reported - Preclinical for Hepatitis in USA (SC)